Keytruda Plus T-VEC Falls Short in Unresectable Melanoma
Pembrolizumab (Keytruda) plus intratumoral talimogene laherparepvec (T-VEC, Imlygic) did not significantly improve survival in unresectable melanoma as compared with pembrolizumab alone, an international phase III trial showed. Although the combination improved median progression-free survival (PFS) by almost 6 months (14.3 vs 8.5 months), the difference did not achieve statistical significance (P=0.13). Median overall survival (OS) […]